<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-107292</identifier>
<setSpec>0214-1221</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Botulínic toxin type a in the treatment of children with neurogenic bladder</dc:title>
<dc:description xml:lang="en">Introduction. Botulinum toxin A (BoNTA) is an alternative in children with neurogenic bladder refractory to anticholinergics. Objective. To evaluate the initial effects of BoNTA in neurogenic bladders .Patients and Methods. 12 patients (9 myelomeningoceles,1tetheredcord, 1 medullary astrocytoma, 1 Ewing&#146;s sarcoma) were studied. The pretreatment evaluation included: voiding diary, incontinence score, renovesicalultra sound, cystourethrography and urodynamic parameters. Patients received 300 UI of BoNTA via detrusor injections. They were re-evaluated at months 1, 3 and 6. After the third control, if improvement was confirmed, patients were injected again. Otherwise, surgery was indicated. Results. After the initial injection, 50% of patients achieved complete continence and 20% remained with minimal leaks. The mean maximum bladder capacity increased from 264 ± 117 ml to 324 ± 170 ml(P=0.322). The mean detrusor pressure decreased from 46 ± 17 cm H2Oto 42 ± 14 cm H2O (P=0.596). The mean bladder compliance increased (..) (AU)</dc:description>
<dc:creator>Durán, V</dc:creator>
<dc:creator>Burek, C</dc:creator>
<dc:creator>Paz, E</dc:creator>
<dc:creator>Weller, S</dc:creator>
<dc:creator>López, J. C</dc:creator>
<dc:creator>Sager, C</dc:creator>
<dc:creator>Corbetta, J. P</dc:creator>
<dc:creator>Bortagaray, J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción. La toxina botulínica A (ToxBA) es una alternativa en niños refractarios a anticolinérgicos. Objetivo. Evaluar los efectos &#147;iniciales&#148; de ToxBA en vejigas neurogénicas .Pacientes y métodos. Se estudiaron 12 pacientes. Las etiologíasfueron: 9 mielomeningocele; 1 médula anclada; 1 astrocitoma medulary 1 sarcoma Ewing. La evaluación pretratamiento incluyó: cartilla-score de incontinencia, ecografía renovesical, cistouretrografía y urodinamia. Se inyectaron 300 UI de ToxBA en detrusor. Se reevaluaron al1, 3 y 6 meses. Si se constataba mejoría se reinyectaban. De lo contrario, se indicaba cirugía. Resultados. Luego de la inyección inicial, 50% de los pacientes alcanzaron la continencia y 20% permanecieron con mínimas fugas. La media de la capacidad vesical máxima se incrementó de 264 ± 117 mla 324 ± 170 ml (P=0,322). La media de la presión del detrusor disminuyó de 46 ± 17 cm H2O a 42 ± 14 cm H2O (P=0,596). La media de la complacencia se incremento de 7,6 ± 5,9 ml/cm H2O a 10,4 ± 6,4 ml/cmH2O (P=0,290). Las contracciones miccionales reflejas desaparecieron (..) (AU)</dc:description>
<dc:source>Cir Pediatr;24(1): 38-43, ene. 2011.</dc:source>
<dc:identifier>ibc-107292</dc:identifier>
<dc:title xml:lang="es">Toxina botulínica-A en el tratamiento de niños con vejiga neurogénica</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d29315</dc:subject>
<dc:subject>^d4151^s22080</dc:subject>
<dc:subject>^d12428^s22054</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d14963^s22021</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d33081^s22073</dc:subject>
<dc:subject>^d1775^s22057</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d14949^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>201101</dc:date>
</metadata>
</record>
</ibecs-document>
